Walter Public Investments Inc. Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Walter Public Investments Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.2% during the third quarter, Holdings Channel.com reports. The firm owned 89,764 shares of the company’s stock after buying an additional 3,634 shares during the period. Johnson & Johnson makes up 5.1% of Walter Public Investments Inc.’s holdings, making the stock its 4th biggest holding. Walter Public Investments Inc.’s holdings in Johnson & Johnson were worth $14,664,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in Johnson & Johnson during the second quarter valued at approximately $39,000. Cardinal Capital Management Inc. lifted its position in Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the last quarter. First Bank & Trust lifted its position in Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at approximately $84,000. 67.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Bank of America decreased their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Barclays initiated coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target for the company. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Insider Activity

In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock worth $52,311,677 over the last 90 days. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $173.43 on Friday. The firm has a market cap of $453.43 billion, a PE ratio of 24.15, a P/E/G ratio of 3.45 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm’s fifty day moving average is $176.32 and its 200 day moving average is $171.55. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business earned $2.60 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.